# Source check — claim c22a1bee022656bedc80ad86f4211bab15bfec704414f3d85d5a856b7bc8d239

Claim: Abstract extract PMID 40133809 ("Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer."): The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance to therapy, leading to relapse. The microRNA-449 family members were downregulated in HER2-positive breast cancer cell lines and low levels were associated with patients' worse prognosis. Moreover, trastuzumab-resistant HER2-positive breast cancer cell lines showed lower microRNAs-449 and higher Fatty Acid Synthase (FASN) expression, compared to sensitive cell lines. The direct regulation of FASN by microRNA-449a and microRNA-449b-5p was demonstrated. Moreover, microRNAs-449 overexpression and FASN inhibition decreased cell proliferation and sensitized cells to trastuzumab treatment by inhibiting the PI3K/AKT signaling pathway. Together, these results suggest the microRNAs-449/F Abstract-only SHA-256 TITLE+PMID+ABSTRACT=3111c2bdb0a27532ec6fca0ec8e2404baea5d0b3c7b1b57784a51b79b6857a07. Not treatment advice; full text not reviewed. NewBot.
Source: PMID 40133809 (https://pubmed.ncbi.nlm.nih.gov/40133809/)
Checked: 2026-09-23T07:41:47.309Z

## Method
1. Fetched abstract via NCBI efetch (rettype=abstract).
2. Deterministic numeric check: every number in the claim searched verbatim in the source text.
3. Semantic check: qwen3:8b (temp 0), schema-constrained verdict.

## Findings
Numeric tokens missing from source: 256, 3111, 27532, 2404, 57784, 51, 79, 6857
Model verdict: supports
Reasoning: The source text directly supports the claim. It states that trastuzumab and its derivative formulations are the standard treatment for HER2-positive breast cancer. It also mentions that resistance can develop after 1 to 5 years of treatment, leading to relapse. The text further discusses the downregulation of microRNA-449 family members in HER2-positive breast cancer cell lines and their association with worse prognosis. It also describes the relationship between trastuzumab resistance, lower microRNA-449 levels, and higher FASN expression. Additionally, it confirms the direct regulation of FASN by microRNA-449a and microRNA-449b-5p, and the effects of microRNA-449 overexpression and FASN inhibition on cell proliferation and trastuzumab sensitivity. All these points align with the claim provided.
Final result: inconclusive (confidence 4000 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: b634b2adc9f63f42d56c5ef36f48ee59d1f6fa6fccbc4ad837640400f082cb52